Close Menu

This article from Forbes reports on a new venture capital fund started by three former executives of Millennium Pharmaceuticals: Mark Levin, Kevin Starr, and Bob Tepper. They just raised $378 million for what they're calling Third Rock Ventures. According to the article, the fund will be closely managing startup companies, and will "only look at a few biotechs, each getting a few tens of millions of dollars."

 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.

Researchers in France are developing a new, fast test for SARS-CoV-2 that initial testing indicates may be highly accurate, the Guardian says.

In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.